April 30, 2009

FDA Mandates Serious Warnings for Botox, All Botulinum Toxin Products

The FDA has ordered its most serious safety warning be attached to all botulinum toxin products due to reports of serious adverse reactions and also due to risks associated with the lack of interchangeability among the three licensed botulinum toxin products. The FDA will now require manufacturers to add black box warning to labels, issue new medication guides, and implement a Risk Evaluation Management Strategy (REMS) for each product. There are now three FDA-approved botulinum toxin products: Botox and Botox Cosmetic made by Allergan, Myobloc manufactured by Solstice Neurosciences, and Dysport made by Ipsen, which just yesterday received FDA approval to treat cervical dystonia. Reports indicate that the botulinum toxin may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism, including unexpected loss of strength or muscle weakness, hoarseness or trouble talking, loss of bladder control, trouble breathing, trouble swallowing, double vision, slurred speech, blurred vision, and drooping eyelids. These symptoms have mostly been reported in children with cerebral palsy being treated with the products for muscle spasticity (an unapproved use of the drugs), but the symptoms have also been reported in adults treated both for approved and unapproved uses. Botulinum toxin products have only been approved by FDA for one or more of the following uses: temporary improvement in the appearance of glabellar lines, treatment of strabismus, blepharospasm, cervical dystonia, and primary axillary hyperhidrosis.

"Updated labels for this class of products will help health care professionals and patients better understand the risks and benefits," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "Botulinum toxin products have benefits but can cause serious health problems and it is important that anyone who administers or uses these products understands these risks."

At a press briefing on April 30, 2009, Ellis F. Unger, M.D., the FDA's acting Deputy Director of the Office of Drug Evaluation I at the Center for Drug Evaluation and Research, said safety has not been an issue when botulinum toxin is used properly for cosmetic purposes, such as smoothing frown lines. Although he did not disclose the number of adverse events, Dr. Unger said there have also been reports of hospitalizations for aspiration pneumonia and respiratory depression, including cases where patients required ventilators. There have also been a small number of deaths, he said. Officials believe that most of the problems occurred when one product was substituted for another without corresponding dose adjustments.

Click here to view FDA Press Release dated 4/30/09

Click here to view more about Botulinum Toxin Products


Best Law Firms Badge 2010 Best Law Firms Badge 2011-2012 Best Law Firms Badge 2013 Best Law Firms Badge 2014 Best Law Firms Badge 2015 Listed in Best Lawyers 2015 2015 Legal Leaders - Top Rated Lawyers Best Law Firms Badge 2016 American Board of Trial Advocates
Super Lawyers Badge for C. Todd Alley Super Lawyers Badge for Don Greiwe Super Lawyers Badge for James D. Clark National Board of Trial Advocacy Badge The National Trial Lawyers Badge 2015 Bay Area Legal Sustaining Law Firm
AV Preeminent Badge for James D. Clark AV Preeminent Badge for Donald G. Greiwe AV Preeminent Badge for C. Todd Alley AV Preeminent Badge for Alley, Clark & Greiwe

Contact Us

Alley, Clark & Greiwe

Street Address
201 N. Franklin, 7th Floor,
Tampa, FL 33602

General Email Inquiries:

Call Us 1-813-222-0977

P (813) 222-0977 | F (813) 224-0373

Free Case Evaluation